Artelo 10-Q: $4.4M Cash, Going Concern Doubt, $8.8M Nine-Month Cash Burn
ARTL sits 17% above its 52-week low of $1.91 on light trading volume (0.1× avg).
Summary
Artelo's Q3 2026 10-Q shows $4.4 million of cash against an $8.8 million nine-month operating burn, with management repeating substantial doubt about going-concern status and flagging that its public float value sits near Nasdaq's $1 million minimum.
Key Events · Earnings and Guidance · ARTL
-
Going Concern Doubt Reiterated
The 10-Q states conditions raise substantial doubt about the company's ability to continue as a going concern within one year after the financial statements are issued.
-
Cash of $4.4M vs $8.8M Burn
Cash and cash equivalents were $4,437 thousand at September 30, 2026 versus $600 thousand at December 31, 2025, while net cash used in operating activities was $8,849 thousand for the nine months.
-
Financings Funded the Period
Net proceeds from common share issuance were $13,069 thousand, including $10,033 thousand net from the March 2026 private placement and $3,037 thousand net from 432,062 ATM shares.
-
Nasdaq Public Float Near Minimum
A new risk factor discloses the market value of publicly held shares was approximately $2 million as of November 11, 2026, close to the $1 million continued-listing minimum.
Analysis · ARTL · Life Sciences
Artelo closed September 30, 2026 with $4.4 million in cash after raising roughly $13.1 million net from share sales in the first nine months, yet the report repeats substantial doubt about its ability to continue as a going concern within a year. The nine-month operating cash burn of $8.8 million is more than double the $4.4 million cash balance, so another raise is required — and the company's own new risk factor notes the market value of publicly held shares was only about $2 million as of November 11, 2026, close to Nasdaq's $1 million minimum. Funding for the period came from the March 2026 private placement ($11.0 million gross, $10.0 million net) and the ATM (432,062 shares for $3.0 million net), but the equity line and shelf are constrained by the one-third-of-public-float limit. Meanwhile, the Craft Capital FINRA arbitration, seeking an $880,000 success fee plus warrants valued at $880,000, remains unresolved with no liability recorded.
How filings like this one have moved
In the 30 days to Nov 11, 2026, 48.1% of the 1752 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ARTL was trading at $2.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2M. The 52-week trading range was $1.91 to $179.19. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.